Adaptive Biotechnologies ADPT Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's deferred revenue?
- Adaptive Biotechnologies (ADPT) reported deferred revenue of $49.4M in Q1 2026.
- How has Adaptive Biotechnologies's deferred revenue changed year-over-year?
- Adaptive Biotechnologies's deferred revenue decreased by 9.9% year-over-year, from $54.81M to $49.4M.
- What is the long-term trend for Adaptive Biotechnologies's deferred revenue?
- Over 5 years (2020 to 2025), Adaptive Biotechnologies's deferred revenue has grown at a -9.2% compound annual growth rate (CAGR), from $73.32M to $45.19M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.